Bristol-Myers Squibb Canada Co. announced last Friday the company reached an agreement with the pan-Canadian Pharmaceutical Alliance for the immuno-oncology treatment Opdivo, or nivolumab, bringing patients with advanced, difficult-to-treat cancers closer to accessing a new treatment option.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
